Kochurani Puthumana, MD
Internal Medicine · Colonial Heights, VANPI 1184662173
Payments from drug & device makers
Across 117 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$405
- Astellas Pharma US Inc$203
- AstraZeneca$203
- Novo Nordisk$178
- AbbVie$142
- Boehringer Ingelheim$127
- plus $947 from 21 others
What the payments were for
- Food & beverage$2,11696%
- Education$894%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 21 | $405 |
| Astellas Pharma US Inc | 8 | $203 |
| AstraZeneca | 12 | $203 |
| Novo Nordisk | 11 | $178 |
| AbbVie(2 entities) | 9 | $142 |
| Boehringer Ingelheim | 6 | $127 |
| Johnson & Johnson | 5 | $105 |
| Pfizer | 6 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| Merck | 5 | $83 |
| Novartis | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| Lilly USA, LLC | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 1 | $41 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Abbott | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Bayer | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$2,205 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $69,421 |
| JardianceEmpagliflozin | 57 | $69,097 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $66,420 |
| XareltoRivaroxaban | 41 | $43,161 |
| EliquisApixaban | 43 | $39,648 |
| FarxigaDapagliflozin Propanediol | 36 | $34,479 |
| RybelsusSemaglutide | 34 | $33,530 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $24,509 |
| LinzessLinaclotide | 26 | $21,063 |
| MyrbetriqMirabegron | 29 | $19,689 |
| JanuviaSitagliptin Phosphate | 21 | $17,787 |
| EntrestoSacubitril/Valsartan | 15 | $15,502 |
| Repatha SureclickEvolocumab | 15 | $12,780 |
| MounjaroTirzepatide | 11 | $11,476 |
| TradjentaLinagliptin | 13 | $8,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $178 | $102,95185 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $127 | $85,07782 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $405 | $71,68576 claims |
| MerckJanumet Xr, Januvia, Dulera | $83 | $46,60667 claims |
| Johnson & JohnsonXarelto | $105 | $43,16141 claims |
| AstraZenecaFarxiga, Symbicort | $203 | $40,12253 claims |
| PfizerEliquis | $105 | $39,64843 claims |
| AbbVieLinzess, Synthroid | $142 | $23,92067 claims |
| Astellas Pharma US IncMyrbetriq | $203 | $19,68929 claims |
| NovartisEntresto | $59 | $15,50215 claims |
| Lilly USA, LLCMounjaro | $49 | $11,47611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Colonial Heights
- Kishor DabhiColonial Heights$40K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.